• Yungjin Pharm corrected its disclosure to extend a product supply contract with MYLAN SEIYAKU LTD through Oct. 9, 2027.
• The agreement covers exclusive supply of cephalosporin injectable antibiotics for Japan, signed Oct. 10, 2020.
• Contract value remains KRW 12.24 billion, equal to 5.5% of 2019 sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Yungjin Pharm. Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261008800579), on October 08, 2026, and is solely responsible for the information contained therein.